BackKrystal Biotech Overview

Krystal Biotech Current Cash

Track Krystal Biotech's current cash ($500M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$501.31M
↑ 62.36% YoYΔ $192.54M vs prior year quarter

Peer average

Loading

Krystal Biotech Current Cash History

Loading

Krystal Biotech vs. peers: Current Cash Comparison

Loading

Krystal Biotech Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Krystal Biotech (KRYS) FAQ

Krystal Biotech (KRYS) currently reports a current cash of $500M as of March 2026. That compares with $310M in the prior-year period — up 62.4% year over year. Use the charts on this page to explore Krystal Biotech's current cash history and peer comparisons.

Krystal Biotech's current cash increased from $310M to $500M — a 62.4% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Krystal Biotech reported $500M in current cash as of March 2026. That compares with $310M in the prior-year period — up 62.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current current cash of $500M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Krystal Biotech, and consider following KRYS for alerts when major investors trade the stock.

Krystal Biotech is classified in the Healthcare sector. On current cash, it currently shows $500M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing KRYS with unrelated industries.